US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polyrizon Ltd.

15.12

+3.6131.36%

Post-market: 15.120.00000.00%19:54 EST

Volume:235.45K

Turnover:3.34M

Market Cap:15.75M

PE:-21.25

High:16.00

Open:12.91

Low:12.44

Close:11.51

52wk High:2,235.00

52wk Low:2.88

Shares:1.04M

Float Shares:996.80K

Volume Ratio:4.94

T/O Rate:23.62%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7114

ROE:-12.20%

ROA:-22.25%

PB:0.86

PE(LYR):- -

Loading ...

Overview Company News Filings

Polyrizon initiates key usability study program for NASARIX

Polyrizon Advances Regulatory Path With Initiation of Usability Study Program for Nasarix™ Allergy Blocker

THOMSON REUTERS

Polyrizon announces board authorized exploration of investment opportunities

BRIEF-Polyrizon Ltd To Explore Revenue-Generating Investment Opportunities In High-Growth Sectors

Polyrizon Ltd: Board Has Approved Pursing Selective Investments That Are Expected to Generate Near-Term Revenues

THOMSON REUTERS

Polyrizon - Focusing Its Initial Efforts on Operating Companies in High-Potential Sectors, Including Defense, Aviation, and AI

THOMSON REUTERS

Polyrizon Ltd: to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors

THOMSON REUTERS

Polyrizon Ltd. Announces Plans to Explore Revenue-Generating Investments in Defense, Aviation, and AI Sectors While Advancing Core Intranasal Medical Pipeline

BRIEF-Polyrizon Expects Nasarix Introduction Aligned With Clinical Progress

Polyrizon's PL-14 Outperforms Standard Nasal Barrier in Blocking Allergens

Polyrizon Submits FDA Pre-Request for Designation for PL-16 Nasal Spray

BRIEF-Polyrizon To Explore Investment In Revenue-Generating Real Assets

Polyrizon Ltd - to Explore Investment in Revenue-Generating Real Assets

THOMSON REUTERS

Polyrizon Ltd. to Explore Revenue-Generating Real Asset Investments While Continuing Development of Core Medical Pipeline

Polyrizon Submits Pre-Request for FDA Designation for PL-16 Viral Blocker

Polyrizon Submits Pre-Request for Designation to FDA for Pl-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

THOMSON REUTERS

Polyrizon Reports Intranasal Naloxone Hydrogel Matches Marketed Product in Rapid Permeation

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

THOMSON REUTERS

BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray

Polyrizon Completes FDA Pre-Submission Meeting for Pl-14 Allergy Blocker Nasal Spray

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PLRZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":15.12,"timestamp":1770066000000,"preClose":11.51,"halted":0,"volume":235451,"hourTrading":{"tag":"盘后","latestPrice":15.12,"preClose":15.12,"latestTime":"19:54 EST","volume":3652,"amount":54734.96,"timestamp":1770080070089,"change":0,"changeRate":0,"amplitude":0.078042},"delay":0,"changeRate":0.313640312771503,"floatShares":996800,"shares":1041700,"eps":-0.71144193,"marketStatus":"Not Yet Opened","change":3.61,"latestTime":"02-02 16:00:00 EST","open":12.91,"high":16,"low":12.44,"amount":3339565.406896,"amplitude":0.309296,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.71144193,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770109200000},"marketStatusCode":0,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":11.51,"preHourTrading":{"tag":"盘前","latestPrice":12.92,"preClose":11.51,"latestTime":"09:29 EST","volume":7389,"amount":92475.10836,"timestamp":1770042596023,"change":1.41,"changeRate":0.122502,"amplitude":0.129453},"postHourTrading":{"tag":"盘后","latestPrice":15.12,"preClose":15.12,"latestTime":"19:54 EST","volume":3652,"amount":54734.96,"timestamp":1770080070089,"change":0,"changeRate":0,"amplitude":0.078042},"volumeRatio":4.942089},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":996800,"roa":"-22.25%","roe":"-12.20%","lyrEps":0,"volumeRatio":4.942089,"shares":1041700,"dividePrice":0,"high":16,"amplitude":0.309296,"preClose":11.51,"low":12.44,"week52Low":2.88,"pbRate":"0.86","week52High":2235,"institutionHeld":0,"latestPrice":15.12,"eps":-0.71144193,"divideRate":0,"volume":235451,"delay":0,"ttmEps":-0.71144193,"open":12.91,"prevYearClose":8.49,"prevWeekClose":11.51,"prevMonthClose":11.51,"prevQuarterClose":8.49,"fiveDayClose":15.37,"twentyDayClose":12.75,"sixtyDayClose":5.9004},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-28","symbol":"PLRZ","defaultRemindTime":1764340200000,"type":"split","dateTimestamp":1764306000000,"forFactor":6,"toFactor":1,"ratio":6},{"market":"US","date":"2025-05-27","symbol":"PLRZ","defaultRemindTime":1748352600000,"type":"split","dateTimestamp":1748318400000,"forFactor":250,"toFactor":1,"ratio":250}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2026-01-30","current":-21.252613,"percent":0.089744,"low":-29.515607,"twenty":-11.278891,"median":-5.035187,"eighty":-1.871075,"high":-0.011381,"avg":-6.919154,"sd":6.080238,"marketCap":20912571},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-25","current":-0.947483,"twenty":-5.174691,"median":-3.5049,"eighty":-1.520317,"marketCap":1463861},{"date":"2025-05-02","current":-0.687943,"twenty":-5.159991,"median":-3.434137,"eighty":-1.353625,"marketCap":1062872},{"date":"2025-05-09","current":-2.602277,"twenty":-5.095085,"median":-3.375088,"eighty":-1.466019,"marketCap":4020518},{"date":"2025-05-16","current":-0.039201,"twenty":-5.02132,"median":-3.354145,"eighty":-1.299871,"marketCap":60566},{"date":"2025-05-23","current":-0.018499,"twenty":-5.006408,"median":-3.310183,"eighty":-1.057434,"marketCap":28581},{"date":"2025-05-30","current":-0.022023,"twenty":-4.999463,"median":-3.245278,"eighty":-1.021327,"marketCap":34025},{"date":"2025-06-06","current":-0.014912,"twenty":-4.937359,"median":-3.214447,"eighty":-0.978975,"marketCap":23039},{"date":"2025-06-13","current":-0.018851,"twenty":-4.922267,"median":-3.183486,"eighty":-0.945854,"marketCap":29125},{"date":"2025-06-20","current":-0.013358,"twenty":-4.871782,"median":-3.155299,"eighty":-0.895899,"marketCap":20638},{"date":"2025-06-27","current":-2.431375,"twenty":-4.817057,"median":-3.116926,"eighty":-0.895899,"marketCap":3756474},{"date":"2025-07-03","current":-2.428961,"twenty":-4.79003,"median":-3.054617,"eighty":-0.90676,"marketCap":3752744},{"date":"2025-07-11","current":-2.469311,"twenty":-4.75787,"median":-3.036282,"eighty":-0.929565,"marketCap":3815085},{"date":"2025-07-18","current":-3.343916,"twenty":-4.728069,"median":-3.039365,"eighty":-0.942596,"marketCap":5166350},{"date":"2025-07-25","current":-4.793774,"twenty":-4.784488,"median":-3.066787,"eighty":-0.954976,"marketCap":7406381},{"date":"2025-08-01","current":-9.134632,"twenty":-4.922267,"median":-3.137242,"eighty":-0.969039,"marketCap":14113006},{"date":"2025-08-08","current":-8.476938,"twenty":-5.004125,"median":-3.155299,"eighty":-0.973817,"marketCap":13096869},{"date":"2025-08-15","current":-8.18463,"twenty":-5.134029,"median":-3.19779,"eighty":-0.976803,"marketCap":12645253},{"date":"2025-08-22","current":-7.746168,"twenty":-5.410414,"median":-3.21607,"eighty":-0.982233,"marketCap":11967829},{"date":"2025-08-29","current":-7.600014,"twenty":-5.856236,"median":-3.245278,"eighty":-0.987228,"marketCap":11742021},{"date":"2025-09-05","current":-7.819245,"twenty":-6.049761,"median":-3.325781,"eighty":-0.992223,"marketCap":12080733},{"date":"2025-09-12","current":-7.143282,"twenty":-6.209629,"median":-3.343916,"eighty":-1.006667,"marketCap":11036370},{"date":"2025-09-19","current":-10.354516,"twenty":-6.696876,"median":-3.375088,"eighty":-1.026648,"marketCap":11742021},{"date":"2025-09-26","current":-11.070023,"twenty":-7.035762,"median":-3.443585,"eighty":-1.030557,"marketCap":12553406},{"date":"2025-10-03","current":-11.383325,"twenty":-7.364852,"median":-3.487865,"eighty":-1.042883,"marketCap":12908691},{"date":"2025-10-10","current":-13.054272,"twenty":-7.512322,"median":-3.569805,"eighty":-1.058791,"marketCap":14803545},{"date":"2025-10-17","current":-11.174457,"twenty":-7.59231,"median":-3.644879,"eighty":-1.068565,"marketCap":12671834},{"date":"2025-10-24","current":-11.278891,"twenty":-7.731553,"median":-3.707687,"eighty":-1.123948,"marketCap":12790262},{"date":"2025-10-31","current":-10.75672,"twenty":-7.950784,"median":-3.905854,"eighty":-1.280758,"marketCap":12198121},{"date":"2025-11-07","current":-9.567215,"twenty":-8.038476,"median":-3.996712,"eighty":-1.310622,"marketCap":10849222},{"date":"2025-11-14","current":-8.045608,"twenty":-8.360015,"median":-4.312242,"eighty":-1.376104,"marketCap":9123720},{"date":"2025-11-21","current":-6.109399,"twenty":-8.170015,"median":-4.417419,"eighty":-1.474489,"marketCap":6928059},{"date":"2025-11-28","current":-5.587228,"twenty":-8.111553,"median":-4.501561,"eighty":-1.508371,"marketCap":6335917},{"date":"2025-12-05","current":-25.23826,"twenty":-8.403861,"median":-4.535397,"eighty":-1.515701,"marketCap":28620187},{"date":"2025-12-12","current":-21.591766,"twenty":-8.696169,"median":-4.627772,"eighty":-1.520317,"marketCap":24485063},{"date":"2025-12-19","current":-17.597159,"twenty":-9.06593,"median":-4.711914,"eighty":-1.541633,"marketCap":19955178},{"date":"2025-12-26","current":-13.245735,"twenty":-9.27961,"median":-4.754698,"eighty":-1.546299,"marketCap":15020663},{"date":"2026-01-02","current":-14.777436,"twenty":-10.201257,"median":-4.798393,"eighty":-1.579229,"marketCap":16757612},{"date":"2026-01-09","current":-23.341039,"twenty":-10.662157,"median":-4.922267,"eighty":-1.630419,"marketCap":26468738},{"date":"2026-01-16","current":-21.842963,"twenty":-11.038692,"median":-4.999213,"eighty":-1.702674,"marketCap":24769920},{"date":"2026-01-23","current":-22.02569,"twenty":-11.165081,"median":-5.003554,"eighty":-1.780942,"marketCap":24977133},{"date":"2026-01-30","current":-18.441421,"twenty":-11.278891,"median":-5.035187,"eighty":-1.871075,"marketCap":20912571}],"updateTime":1770097802772},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605974414","title":"Polyrizon initiates key usability study program for NASARIX","url":"https://stock-news.laohu8.com/highlight/detail?id=2605974414","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605974414?lang=en_us&edition=fundamental","pubTime":"2026-01-22 22:31","pubTimestamp":1769092283,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the initiation of a key usability study program for its lead product candidate, NASARIX, an intranasal allergy blocker d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-initiates-key-usability-study-program-for-nasarix-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-initiates-key-usability-study-program-for-nasarix-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2605492701","title":"Polyrizon Advances Regulatory Path With Initiation of Usability Study Program for Nasarix™ Allergy Blocker","url":"https://stock-news.laohu8.com/highlight/detail?id=2605492701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605492701?lang=en_us&edition=fundamental","pubTime":"2026-01-22 22:25","pubTimestamp":1769091900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUA81KWXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603368761","title":"Polyrizon announces board authorized exploration of investment opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2603368761","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603368761?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:55","pubTimestamp":1768312515,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) recently announced that its Board of Directors has authorized the exploration of strategic investment opportunities in select reve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-board-authorized-exploration-of-investment-opportunities-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-board-authorized-exploration-of-investment-opportunities-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603682777","title":"BRIEF-Polyrizon Ltd To Explore Revenue-Generating Investment Opportunities In High-Growth Sectors","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682777","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682777?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:43","pubTimestamp":1768311783,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Ltd To Explore Revenue-Generating Investment Opportunities In High-Growth SectorsJan 13 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON LTD: TO EXPLORE REVENUE-GENERATING INVESTMENT OPPORTU","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE13D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2603822316","title":"Polyrizon Ltd: Board Has Approved Pursing Selective Investments That Are Expected to Generate Near-Term Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2603822316","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603822316?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:40","pubTimestamp":1768311610,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE13D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603682298","title":"Polyrizon - Focusing Its Initial Efforts on Operating Companies in High-Potential Sectors, Including Defense, Aviation, and AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682298?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:40","pubTimestamp":1768311610,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE13D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603682239","title":"Polyrizon Ltd: to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682239","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682239?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:40","pubTimestamp":1768311610,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE13D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603682142","title":"Polyrizon Ltd. Announces Plans to Explore Revenue-Generating Investments in Defense, Aviation, and AI Sectors While Advancing Core Intranasal Medical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682142","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682142?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:39","pubTimestamp":1768311550,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. Announces Plans to Explore Revenue-Generating Investments in Defense, Aviation, and AI Sectors While Advancing Core Intranasal Medical Pipeline. Polyrizon Ltd. has announced a strategic initiative to explore selective investments in revenue-generating assets, focusing on companies operating in high-potential sectors such as defense, aviation, and artificial intelligence. The company aims to utilize its strong cash position and debt-free balance sheet to generate near-term revenues, enhance financial stability, and create additional shareholder value. While pursuing these opportunities, Polyrizon will continue to prioritize the advancement of its core intranasal medical device pipeline, including ongoing product development, preclinical and clinical studies, and regulatory progress for products such as PL-14, PL-16, and the Trap & Target platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL5lpmF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","SG9999014021.USD","PLRZ","LU2210149790.SGD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","SG9999014039.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2601955398","title":"BRIEF-Polyrizon Expects Nasarix Introduction Aligned With Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2601955398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601955398?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:39","pubTimestamp":1767883173,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Expects Nasarix Introduction Aligned With Clinical ProgressJan 8 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON LTD - EXPECTS NASARIX INTRODUCTION ALIGNED WITH CLINICAL PROGRESSSource text: ID:nGNX9G0DclFurther company coverage: PLRZ.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2601588265","title":"Polyrizon's PL-14 Outperforms Standard Nasal Barrier in Blocking Allergens","url":"https://stock-news.laohu8.com/highlight/detail?id=2601588265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601588265?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:07","pubTimestamp":1767622031,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd., a pre-clinical-stage biotechnology company, announced positive results from a new in-vitro pre-clinical study evaluating its PL-14 Allergy Blocker formulation. The study assessed PL-14's ability to block the transfer of Der p 1, a major house dust mite allergen, in a validated laboratory model simulating nasal tissue. Results showed that PL-14 significantly outperformed hydroxypropyl methylcellulose , a standard nasal barrier comparator, by maintaining much lower allergen permeation at all tested time points. PL-14 achieved a maximum mean allergen level of approximately 141.2 ng at 4 hours, compared to HPMC's 5201.2 ng at 24 hours. Polyrizon plans to use these findings to support future clinical studies aimed at establishing PL-14's regulatory pathway and clinical benefits for allergy prevention. The company did not specify if or when these results will be presented at a scientific meeting.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLc0vLNy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","BK4585","SG9999014039.USD","LU2210150020.SGD","PLRZ","NDAQ","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2600065165","title":"Polyrizon Submits FDA Pre-Request for Designation for PL-16 Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2600065165","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600065165?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:30","pubTimestamp":1767360616,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. has announced the submission of a Pre-Request for Designation to the U.S. FDA for its PL-16 Viral Blocker, a hydrogel nasal spray designed to reduce exposure to respiratory viruses such as influenza and the common cold. This regulatory step could pave the way for PL-16 to achieve over-the-counter status, offering a non-pharmaceutical, physical barrier against viral infections. No grant or funding involving Polyrizon Ltd. or other beneficiary organizations is mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL5xVMhv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4585","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","BK4588","SG9999014005.SGD","SG9999014013.SGD","BK4112","PLRZ","SG9999014039.USD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2595738149","title":"BRIEF-Polyrizon To Explore Investment In Revenue-Generating Real Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738149","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595738149?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:29","pubTimestamp":1767014962,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon To Explore Investment In Revenue-Generating Real AssetsDec 29 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON LTD - TO EXPLORE INVESTMENT IN REVENUE-GENERATING REAL ASSETSSource text: ID:nGNXbFjZVsFurther company coverage: PLRZ.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nFWN3XX01X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2595787186","title":"Polyrizon Ltd - to Explore Investment in Revenue-Generating Real Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595787186?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:20","pubTimestamp":1767010849,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nFWN3XX01X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2595787134","title":"Polyrizon Ltd. to Explore Revenue-Generating Real Asset Investments While Continuing Development of Core Medical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787134","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595787134?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:20","pubTimestamp":1767010809,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. has announced plans to explore investments in revenue-generating real assets, leveraging its strong cash position and debt-free balance sheet. The company will continue to advance its core medical device pipeline, including product development, preclinical and clinical studies, and regulatory progress for products such as PL-14, PL-16, and the Trap & Target intranasal drug delivery platform. The Board has authorized the search for investment opportunities aimed at generating additional revenue and creating long-term value for shareholders, while maintaining full commitment to its primary medical activities. Polyrizon will provide updates on any significant developments related to these initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL6PLKHz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","PLRZ","BK4585","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD"],"gpt_icon":0},{"id":"2592162755","title":"Polyrizon Submits Pre-Request for FDA Designation for PL-16 Viral Blocker","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162755","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592162755?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:20","pubTimestamp":1766150410,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd., a pre-clinical-stage biotechnology company, has submitted a Pre-Request for Designation  to the U.S. Food and Drug Administration  for its PL-16 Viral Blocker. This non-pharmacological intranasal product is designed to reduce exposure to airborne respiratory viruses, such as influenza and cold viruses, by forming a temporary physical barrier on the nasal mucosa. The Pre-RFD submission initiates a formal regulatory dialogue with the FDA to determine the appropriate regulatory pathway for PL-16 based on its physical mode of action.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 19, 2025, and is solely responsible ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL42QZrZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","PLRZ","SG9999014039.USD","IE00B64PRP62.GBP","BK4585","LU2095319765.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD"],"gpt_icon":0},{"id":"2592170162","title":"Polyrizon Submits Pre-Request for Designation to FDA for Pl-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses","url":"https://stock-news.laohu8.com/highlight/detail?id=2592170162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592170162?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:20","pubTimestamp":1766150400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA62BCZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2590161105","title":"Polyrizon Reports Intranasal Naloxone Hydrogel Matches Marketed Product in Rapid Permeation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590161105","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590161105?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:15","pubTimestamp":1765458914,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd., a biotechnology company focused on intranasal products, has announced promising preclinical results for its proprietary intranasal naloxone hydrogel formulation. The research demonstrated that the hydrogel offers significantly enhanced tissue retention compared to a currently marketed intranasal naloxone product, without compromising the rapid drug permeation required for emergency opioid overdose treatment. The results, which include stability, mucoadhesion, and permeability studies, reinforce the potential of Polyrizon's Trap & Target technology to deliver improved performance in real-world scenarios. The company has already completed these studies and announced the findings, positioning the product for further development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL4kvcTj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014005.SGD","BK4112","LU0314104364.USD","BK4588","NDAQ","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","PLRZ","SG9999014013.SGD"],"gpt_icon":0},{"id":"2590516916","title":"Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516916?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:15","pubTimestamp":1765458900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA5KZ4ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2589335638","title":"BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2589335638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589335638?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:56","pubTimestamp":1765202176,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal SprayDec 8 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON COMPLETES FDA PRE-SUBMISSION MEETING FOR PL-14 ALLERGY BLOCKE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA1RNWVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2589356880","title":"Polyrizon Completes FDA Pre-Submission Meeting for Pl-14 Allergy Blocker Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2589356880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589356880?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:55","pubTimestamp":1765202100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA1RNWVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}]}}